LRRK2 Investigative Therapeutics Exchange (LITE) will support new approaches targeting LRRK2, the most common cause of inherited Parkinson’s disease Programme…
Read More »LRRK2 Investigative Therapeutics Exchange (LITE) will support new approaches targeting LRRK2, the most common cause of inherited Parkinson’s disease Programme…
Read More »